By Novo Nordisk…
Novo Nordisk Pharmatech acquires new site to support expanded production
Koege, Denmark: – Leading Recombinant Insulin and quaternary ammonium compounds (Quats) specialist Novo Nordisk Pharmatech A/S has invested in a new plot of land close to its Køge Nord headquarters to support future growth and production expansions.
The 47.000 square meter site land is located less than two kilometers from the existing site in Køge Nord. Its precise intended use will be communicated at a later date.
Novo Nordisk Pharmatech CEO Ulla Grove Krogsgaard Thomsen commented: “With the purchase, the needed space for future expansions is ensured while maintaining the synergies with the nearby headquarters and the interaction with local authorities.”
Ms. Thomsen explained: “For the past six months, we have been looking for a suitable location for our new production facility. Køge Nord is an obvious choice due to the proximity to our existing headquarters and the good infrastructure around Køge.”
“We are creating 50 new jobs in connection with establishing the new facility, and there are good opportunities to expand production even more in the future,” she added.
Welcoming sustainable businesses
Køge Municipality’s Mayor, Marie Stærke, welcomed the acquisition.
“I am happy that a high-profile Danish company like Novo Nordisk Pharmatech chooses to expand its presence here in Køge Municipality,” said Ms. Staerke.
“We would like to develop on the business front by attracting new types of sustainable and innovative production companies within, for example, the technology, food, or pharmaceutical industry – so also in that light, Novo Nordisk Pharmatech is an excellent buyer of the large commercial plot with the good location in Køge Nord,” said the Mayor.
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical raw materials for the pharmaceutical and biopharmaceutical industries. The company specializes in producing quaternary ammonium compounds (Quats) used as active pharmaceutical ingredients (APIs) and excipients as well as delivering Recombinant Insulin for use in cell culture media to enhance cell growth and viability, and productivity.
Novo Nordisk Pharmatech A/S helps the world´s largest pharmaceutical and biopharmaceutical industries reduce their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.
Novo Nordisk Pharmatech A/S was established in 1949 as Ferrosan Fine Chemicals and acquired by Novo Nordisk in 1986. The company is operating as a division of Novo Nordisk A/S from Køge, south of Copenhagen.
You can learn more about Novo Nordisk Pharmatech at novonordiskpharmatech.com.
Click on News from Novo Nordisk Pharmatech to see further Novo Nordisk Pharmatech announcements.